title: Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men.
abstract: Methamphetamine abusers often complain of feelings of depression that can complicate accurately diagnosing these individuals during treatments for methamphetamine abuse. This article presents an examination of temporal associations between documented methamphetamine use and reported ratings of depression among 162 gay and bisexual male methamphetamine abusers who participated in a 16-week randomized clinical trial of four behavioral therapies for methamphetamine abuse. Methamphetamine use was measured using thrice-weekly urine samples analyzed for drug metabolite. Self-reported depressive symptoms were collected weekly using the Beck Depression Inventory (BDI). At treatment entry, 73.2% of participants rated their depressive symptoms as mild or higher in severity (BDI>or=10), with 28.5% reporting BDI scores in the moderate to severe range (BDI>or=19). All participants reported significant decreases in depressive symptoms from baseline through the end of treatment, regardless of treatment condition, HIV status, or mood disorder diagnosis. A mixed regression model showed methamphetamine use for up to 5 days prior to the BDI score strongly predicted depressive symptoms (F1, 968=18.6, P<.0001), while BDI scores had no significant association with subsequent methamphetamine use. Findings show that behavioral methamphetamine abuse treatment yields reductions in methamphetamine use and concomitant depressive symptom ratings that are sustained to 1 year after treatment entry.
authors.affiliation: UCLA Integrated Substance Abuse Programs, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA. jpeck@mednet.ucla.edu
authors.forename: James A
authors.initials: JA
authors.lastname: Peck
authors.forename: Cathy J
authors.initials: CJ
authors.lastname: Reback
authors.forename: Xiaowei
authors.initials: X
authors.lastname: Yang
authors.forename: Erin
authors.initials: E
authors.lastname: Rotheram-Fuller
authors.forename: Steven
authors.initials: S
authors.lastname: Shoptaw
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019969:Amphetamine-Related Disorders / Q000453:epidemiology / Q000523:psychology / Q000628:therapy*; D001521:Behavior Therapy; D001727:Bisexuality / Q000523:psychology*; D003863:Depression / Q000453:epidemiology / Q000523:psychology / Q000628:therapy*; D018023:HIV Seronegativity; D006679:HIV Seropositivity / Q000150:complications; D018451:Homosexuality, Male / Q000523:psychology*; D006801:Humans; D008297:Male; D008694:Methamphetamine; D008875:Middle Aged; D012309:Risk-Taking; D012725:Sexual Behavior
chemical_list: D008694:Methamphetamine
references.citation: West J Med. 1998 Feb;168(2):93-7
references.pmid: 9499742
references.citation: J Psychoactive Drugs. 2003 May;35 Suppl 1:161-8
references.pmid: 12825759
references.citation: Drug Alcohol Depend. 2005 May 9;78(2):125-34
references.pmid: 15845315
references.citation: J Psychoactive Drugs. 1998 Jul-Sep;30(3):239-45
references.pmid: 9798789
references.citation: Neurotox Res. 2002 Jun;4(4):297-313
references.pmid: 12829420
references.citation: J Consult Clin Psychol. 2003 Feb;71(1):53-61
references.pmid: 12602425
references.citation: J Subst Abuse Treat. 2002 Sep;23(2):145-50
references.pmid: 12220612
references.citation: J Addict Dis. 2002;21(1):107-19
references.pmid: 11831496
references.citation: Addiction. 2001 Nov;96(11):1589-601
references.pmid: 11784456
references.citation: J Subst Abuse Treat. 1995 Mar-Apr;12(2):117-27
references.pmid: 7623389
references.citation: Am J Psychiatry. 1993 May;150(5):763-9
references.pmid: 8480823
references.citation: J Stud Alcohol Suppl. 1994 Dec;12:70-5
references.pmid: 7723001
references.citation: J Subst Abuse Treat. 1996 Nov-Dec;13(6):493-7
references.pmid: 9219147
references.citation: J Neuropsychiatry Clin Neurosci. 2000 Fall;12(4):480-4
references.pmid: 11083165
references.citation: J Subst Abuse Treat. 1992;9(3):199-213
references.pmid: 1334156